RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases

Journal of Thoracic Oncology

Volumn 9, Issue 3, 2014, Pages 345-354

  Miller, Robert E ^a   Jones, Jon C ^a   Tometsko, Mark ^a   Blake, Michelle L ^a   Dougall, William C ^a  

^a AMGEN INC   (United States)

Author keywords

Bone metastasis; Lung cancer; Osteolysis; Osteoprotegerin; RANK ligand inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OSTEOPROTEGERIN FC; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BOLUS INJECTION; BONE ATROPHY; BONE DESTRUCTION; BONE METASTASIS; BONE RADIOGRAPHY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTICOAGULANTS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; ENOXAPARIN; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OSTEOLYSIS; OSTEOPROTEGERIN; RANK LIGAND; SURVIVAL RATE; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84894596094     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000070     Document Type: Article

References (32)

1. Al Husaini H, Wheatley-Price P, Clemons M, Shepherd FA. Prevention and management of bone metastases in lung cancer: A review. J Thorac Oncol 2009;4:251-259.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664.
3. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
4. Roodman GD. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-3571.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
6. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
7. McGrath EE. OPG/RANKL/RANK pathway as a therapeutic target in cancer. J Thorac Oncol 2011;6:1468-1473.
8. Bu G, Lu W, Liu CC, et al. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: Implication for breast cancer osteolytic bone metastases. Int J Cancer 2008;123:1034-1042.
9. Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009;23:1882-1894.
10. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-4458.
11. Feeley BT, Liu NQ, Conduah AH, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 2006;21:1571-1580.
12. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-4436.
13. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 2006;23:19-31.
14. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-1244.
15. Li X, Liao J, Park SI, et al. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone 2011;48:1354-1361.
16. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.
17. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: Subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7:1823-1829.
18. Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7:2160-2169.
19. Stocking KL, Jones JC, Everds NE, Buetow BS, Roudier MP, Miller RE. Use of low-molecular-weight heparin to decrease mortality in mice after intracardiac injection of tumor cells. Comp Med 2009;59:37-45.
20. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008;25:119-129.
21. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-Titer recombinant retrovirus. Hum Gene Ther 1996;7:1405-1413.
22. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
23. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-Term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
24. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in nonsmall cell lung cancer: A retrospective study. Lung Cancer 2007;57: 229-232.
25. Dougall WC. Molecular pathways: Osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 2012;18:326-335.
26. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 2013;31:992-1001.
27. Li X, Okada Y, Pilbeam CC, et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology 2000;141:2054-2061.
28. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61:2572-2578.
29. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-822.
30. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
31. Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. RANKL inhibition combined with tamoxifen treatment increases anti-Tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 2012;135:771-780.
32. Chen LM, Kuo CH, Lai TY, et al. RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J Cell Biochem 2011;112:933-941.